6,993 Quest Diagnostics Incorporated $DGX Shares Bought by Nisa Investment Advisors LLC

Key Points

• Nisa Investment Advisors increased its Quest Diagnostics stake by 42.1% in the third quarter, purchasing 6,993 additional shares and bringing its holdings to 23,604 shares valued at approximately $5.5 million.
• Institutional ownership remains high at 88.06%, with several other funds also increasing their positions in Quest Diagnostics during the quarter.
• Quest Diagnostics exceeded quarterly expectations with $3.00 in EPS and $3.10 billion in revenue, while paying a quarterly dividend of $0.86 per share, equivalent to a 1.4% annualized yield.

Nisa Investment Advisors LLC raised its stake in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 42.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,604 shares of the medical research company's stock after purchasing an additional 6,993 shares during the quarter. Nisa Investment Advisors LLC's holdings in Quest Diagnostics were worth $5,501,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Integrated Advisors Network LLC increased its stake in Quest Diagnostics by 41.4% during the third quarter. Integrated Advisors Network LLC now owns 1,769 shares of the medical research company's stock worth $412,000 after acquiring an additional 518 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Quest Diagnostics by 8.7% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 122,316 shares of the medical research company's stock valued at $31,198,000 after purchasing an additional 9,770 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in shares of Quest Diagnostics by 19.7% in the 3rd quarter. Diversify Advisory Services LLC now owns 4,724 shares of the medical research company's stock valued at $1,101,000 after purchasing an additional 778 shares in the last quarter. Prime Capital Investment Advisors LLC lifted its stake in shares of Quest Diagnostics by 257.7% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,416 shares of the medical research company's stock valued at $796,000 after purchasing an additional 2,461 shares in the last quarter. Finally, Net Worth Advisory Group grew its holdings in shares of Quest Diagnostics by 47.5% during the 3rd quarter. Net Worth Advisory Group now owns 7,129 shares of the medical research company's stock worth $1,662,000 after purchasing an additional 2,296 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Stock Performance

Shares of NYSE:DGX opened at $241.49 on Friday. The company has a market cap of $26.65 billion, a P/E ratio of 24.05, a PEG ratio of 2.19 and a beta of 0.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.46 and a current ratio of 1.70. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $248.84. The business's 50-day simple moving average is $237.67 and its 200 day simple moving average is $216.82.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.87 by $0.13. The firm had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. Quest Diagnostics's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.60 EPS. On average, sell-side analysts forecast that Quest Diagnostics Incorporated will post 11.23 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th were paid a dividend of $0.86 per share. The ex-dividend date was Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. Quest Diagnostics's dividend payout ratio (DPR) is currently 36.52%.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Barclays increased their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. UBS Group reaffirmed a "neutral" rating and set a $250.00 price target on shares of Quest Diagnostics in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 28th. Mizuho increased their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Finally, Truist Financial raised their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company a "hold" rating in a research note on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of "Moderate Buy" and a consensus target price of $244.27.

Insider Activity

In other news, CEO J. E. Davis sold 10,000 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total value of $2,427,200.00. Following the completion of the transaction, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the firm's stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares of the company's stock, valued at approximately $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,277 shares of company stock worth $8,316,493 over the last 90 days. Company insiders own 0.88% of the company's stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated NYSE: DGX is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.